Background: The aim of this study was to evaluate the efficacy of Robuvit® (French oak extract, Horphag Research) in improving kidney function in subjects with temporary kidney dysfunction (TKD) and increased oxidative stress levels.
Methods: Fifty-seven subjects with TKD were included in the registry. Subjects were divided into two goups according to albumin levels in the urine. Plasma free radicals were measured in order to evaluate a possible connection with alterations in kidney function. Robuvit® was used at the dose of three capsules/day (300 mg/day) for 4 weeks.
Results: Subjects with micro-albuminuria treated with Robuvit® improved significantly more than controls treated with standard management, achieving a full normalization of albumin levels in the urine (P<0.05). In subjects with macroalbuminuria, the decrease in albumin loss was also significant after four weeks, with better overall results in Robuvit® supplemented patients (P<0.05) than in controls.
Conclusions: Albuminuria, as a significant marker of TKD, can be significantly and safely improved with Robuvit® supplementation.